沃氪医疗美股招股说明书(2025-09-26版)

Prospectus Supplement(To Prospectus dated September 15, 2025) 22,055,096 Class A Ordinary SharesPre-Funded Warrants to purchase up to 16,944,238 Class A Ordinary Shares16,944,238 Class A Ordinary Shares Issuable upon Pre-Funded Warrants WORK Medical Technology Group LTD This is an offering of the securities of WORK Medical Technology Group LTD (the “Company,” “we,” “our,” or “us”), a CaymanIslands exempted company with limited liability, of up to (i) 22,055,096 Class A ordinary shares (each, a “Class A Ordinary Share,”and, collectively, the “Class A Ordinary Shares”), par value $0.0005 per Class A Ordinary Share; and (ii) 16,944,238 pre-fundedwarrants (each, a “Pre-funded Warrant,” and, collectively, the “Pre-Funded Warrants”) to purchase Class A Ordinary Shares (each, a“Pre-funded Warrant Share,” and, collectively, the “Pre-Funded Warrant Shares”) issuable upon exercise of Pre-Funded Warrants,directly to select investors pursuant to this prospectus and the accompanying prospectus at an offering price of US$0.075 per Class AOrdinary Share. Each Pre-Funded Warrant is exercisable for one Class A Ordinary Share for $0.0005 immediately upon issuance until all of the Pre-Funded Warrants are exercised in full. The number of Pre-Funded Warrant Shares are subject to adjustments for stock splits,recapitalizations, and reorganizations. There is no established public trading market for the Pre-Funded Warrants, and we do not expecta market to develop. We do not intend to list the Pre-Funded Warrants on the Nasdaq Capital Market or on any other national securitiesexchange. A holder of Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if the holder, together withits affiliates, would beneficially own in excess of 9.99% of the number of Class A Ordinary Shares outstanding immediately aftergiving effect to such exercise. Each Pre-Funded Warrant will be exercisable for one Class A Ordinary Share. The exercise price of eachPre-Funded Warrant is equal to $0.0005 per share. The Pre-Funded Warrants will be immediately exercisable (subject to the beneficialownership cap) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Our Class A Ordinary Shares are traded on the Nasdaq Capital Market under the symbol “WOK.” On September 24, 2025, the closingprice of our Class A Ordinary Shares as reported by the Nasdaq Capital Market was $0.11. During the year immediately prior to thedate of this prospectus supplement, the high and low closing prices were US$6.51 and US$0.11 per Class A Ordinary Share,respectively. We have recently experienced price volatility in our stock. See related risk factors in our most recent annual report onForm 20-F (the “2024 Annual Report”). The aggregate market value of our outstanding Class A Ordinary Shares held by non-affiliates or public float, as of September 25,2025, was approximately $51,983,491, which was calculated based on 56,999,442 Class A Ordinary Shares held by non-affiliates andthe per share price of $0.912, which was the closing price of our Class A Ordinary Shares on Nasdaq on September 23, 2025. Pursuant to General Instruction I.B.5. of Form F-3, in no event will we sell the securities covered hereby in a public primary offeringwith a value exceeding more than one-third of the aggregate market value of our Class A Ordinary Shares in any 12-month period solong as the aggregate market value of our voting and non-voting common equity held by non-affiliates remains below $75,000,000.During the 12 calendar months prior to and including the date of this prospectus supplement, we have not offered or sold any securitiespursuant to General Instruction I.B.5 of Form F-3. Investing in our securities being offered pursuant to this prospectus supplement involves a high degree of risk. You shouldcarefully read and consider the “Risk Factors” section of this prospectus supplement,and risk factors set forth in the 2024Annual Report, in other reports incorporated herein by reference,and in the prospectus before you make your investmentdecision. We are both an “emerging growth company” and a “foreign private issuer” as defined under the U.S.federal securities laws and, assuch, may elect to comply with certain reduced public company reporting requirements for this and future filings. See “ProspectusSupplement Summary—Implications of Being an Emerging Growth Company” on page S-11, and“Prospectus Supplement Summary—Implications of Being a Foreign Private Issuer” on page 12. As of the date of this prospectus supplement, the Company has 56,999,442 Class A Ordinary Shares with one vote each on all mattersto be decided by way of a poll (56,999,442 votes) and 7,592,500 Class B ordinary shares, par value $0.0005 per share (each, a “ClassB Ordinary Share,” and, collectively, the “Class B Ordinary Shares,” and together with the Class A Ordinary Shares, the “OrdinaryShares”) with 20 votes each on all matters to be decided by wa